Agenus Inc. AGEN

Company Overview

Agenus Inc. is a U.S.-based biotechnology company focused on immuno-oncology, cell therapy, and vaccine-related technologies. The company develops therapies designed to activate or regulate the immune system to treat cancer and infectious diseases, with a primary emphasis on antibody therapeutics, adoptive cell therapies, and proprietary immunotherapy platforms. Agenus operates within the broader biotechnology and pharmaceutical industries, particularly in oncology drug development and immune-based therapeutics.

The company’s primary revenue sources have historically included collaboration agreements, licensing arrangements, milestone payments, and research funding tied to partnerships with larger pharmaceutical companies, alongside limited product-related revenue. Agenus has developed a portfolio of immune checkpoint antibodies and cell therapy technologies through internal research and acquisitions. Its strategic positioning has centered on owning multiple components of the immunotherapy development stack, including antibody discovery, manufacturing capabilities, and cell therapy engineering. Founded in 1994 as Antigenics Inc., the company initially focused on vaccine technologies before evolving into a broader immuno-oncology platform company and later rebranding as Agenus Inc.